A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study

Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week b...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1995-01, Vol.13 (2), p.171-174
Main Authors: Gradishar, W J, Vogelzang, N J, Kilton, L J, Leibach, S J, Rademaker, A W, French, S, Benson, 3rd, A B
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Dose-Response Relationship, Drug
Drug Evaluation
Drugs, Investigational - administration & dosage
Drugs, Investigational - adverse effects
Drugs, Investigational - therapeutic use
Echinomycin - administration & dosage
Echinomycin - adverse effects
Echinomycin - therapeutic use
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Longitudinal Studies
Male
Middle Aged
Sarcoma - drug therapy
Sarcoma - mortality
Sarcoma - secondary
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patient with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly x 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00872868